Deutsche Bank’s Kyverna Therapeutics KYTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$270K Sell
39,736
-5,117
-11% -$40.4K ﹤0.01% 2941
2026
Q2
$400K Buy
44,853
+40,936
+1,045% +$363K ﹤0.01% 2895
2026
Q1
$33.8K Hold
3,917
– – ﹤0.01% 3508
2025
Q4
$36.8K Hold
3,917
– – ﹤0.01% 3485
2025
Q3
$23.5K Hold
3,917
– – ﹤0.01% 3492
2025
Q2
$12K Buy
+3,917
New +$9.7K ﹤0.01% 3502
2025
Q1
– Sell
-4,171
Closed -$15.6K – 3649
2024
Q4
$15.6K Buy
+4,171
New +$20K ﹤0.01% 3499

Other funds holding KYTX

Deutsche Bank's KYTX Position: Q3 2026 in Review

Deutsche Bank reduced its Kyverna Therapeutics (KYTX) stake by 11% in Q3 2026, selling an estimated $40.4K and leaving 39,736 shares worth $270K. The position accounts for ﹤0.01% of the portfolio, ranked #2941.

Deutsche Bank first reported a position in KYTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $400K in Q2 2026. 128 funds tracked by Wall St. Rank hold KYTX as of Q3 2026.

  • Deutsche Bank held 39,736 shares of Kyverna Therapeutics worth $270K as of Q3 2026.
  • Deutsche Bank sold 5,117 Kyverna Therapeutics shares in Q3 2026, an estimated $40.4K.
  • Kyverna Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q3 2026, its #2941 holding.
  • Deutsche Bank first reported a position in Kyverna Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Deutsche Bank's Kyverna Therapeutics position peaked at $400K in Q2 2026.
  • 128 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q3 2026.

Based on Deutsche Bank's 13F filing for Q3 2026, filed 6 Nov 2026.